22:35 , May 17, 2019 |  BC Extra  |  Clinical News

May 17 Clinical Quick Takes: Achillion Phase III plans for PNH combo; plus NCI, MorphoSys

Achillion to start Phase III of PNH combo in 1H20  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will start in 1H20 a Phase III trial evaluating oral CFD inhibitor ACH-4471 in combination with C5 inhibitors to...
21:44 , Feb 12, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
23:31 , Dec 21, 2018 |  BC Extra  |  Company News

Alexion gains early approval for long-acting PNH therapy

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received FDA approval for Ultomiris ravulizumab-cwvz (ALXN1210), the biotech's long-acting formulation of Soliris eculizumab, to treat paroxysmal nocturnal hemoglobinuria. While the approval came nearly two months ahead of the Feb. 18...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...
00:47 , Dec 19, 2018 |  BC Extra  |  Clinical News

Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound....
23:21 , Sep 10, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
23:45 , Aug 21, 2018 |  BC Extra  |  Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
22:48 , May 3, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Sangamo

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said CEO Milind Deshpande will step down. He will be succeeded by President and COO Joseph Truitt. Sangamo Therapeutics Inc. (NASDAQ:SGMO) said SVP and CBO Curt Herberts, III...
21:23 , Feb 26, 2018 |  BC Extra  |  Company News

Achillion rises on positive opinion for C3G therapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday. ACH-4471 is...